SEC Form 4 · accession 0001127602-15-005509
BIOGEN INC. · BIIB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alfred Sandrock
Officer — Grp SVP, Chief Medical Officer
Period of report
Feb 10, 2015
Accepted (ET)
Feb 11, 2015 · 4:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875045
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Feb 10, 2015 | S | 300 | $397.113 | D | 15,417 | D | |
| Common StockF3,F4 | Feb 10, 2015 | S | 643 | $398.095 | D | 14,774 | D | |
| Common Stock | Feb 10, 2015 | S | 100 | $399.08 | D | 14,674 | D | |
| Common Stock | Feb 10, 2015 | S | 100 | $400.22 | D | 14,574 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
- F2This represents the weighted average price for shares sold at a range between $396.87 (low) and $397.34 (high).
- F3Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.
- F4This represents the weighted average price for shares sold at a range between $397.94 (low) and $398.65 (high).